Bone Biologics Corp. Files Amendment No. 2 to S-1 Registration Statement
Ticker: BBLGW · Form: S-1/A · Filed: Feb 26, 2024 · CIK: 1419554
| Field | Detail |
|---|---|
| Company | Bone Biologics Corp (BBLGW) |
| Form Type | S-1/A |
| Filed Date | Feb 26, 2024 |
| Risk Level | low |
| Pages | 14 |
| Reading Time | 17 min |
| Key Dollar Amounts | $729,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: S-1/A, Registration Statement, Public Offering, Bone Biologics, SEC Filing
TL;DR
<b>Bone Biologics Corporation has filed an amendment to its S-1 registration statement, indicating ongoing efforts to register securities for public offering.</b>
AI Summary
Bone Biologics Corp (BBLGW) filed a Amended IPO Registration (S-1/A) with the SEC on February 26, 2024. Bone Biologics Corporation filed an S-1/A on February 26, 2024. The filing is Amendment No. 2 to the Form S-1 Registration Statement. The company is incorporated in Delaware and its fiscal year ends on December 31. The principal executive offices are located at 2 Burlington Woods Drive, Suite 100, Burlington, MA 01803. Jeffrey Frelick is the Chief Executive Officer.
Why It Matters
For investors and stakeholders tracking Bone Biologics Corp, this filing contains several important signals. This amendment suggests Bone Biologics is actively pursuing a public offering, which could provide capital for operations and growth. The S-1/A filing is a necessary step for companies looking to raise funds through the sale of securities to the public.
Risk Assessment
Risk Level: low — Bone Biologics Corp shows low risk based on this filing. The filing is an S-1/A, which is a routine amendment for a registration statement and does not contain new financial data or significant business updates that would alter the risk profile.
Analyst Insight
Monitor future filings for updates on the registration statement's effectiveness and details of the proposed public offering.
Key Numbers
- 2024-02-26 — Filing Date (Amendment No. 2 to Form S-1)
- 333-276771 — Registration Statement Number (SEC Filing)
Key Players & Entities
- Bone Biologics Corporation (company) — Registrant
- February 26, 2024 (date) — Filing date
- Delaware (jurisdiction) — State of incorporation
- Jeffrey Frelick (person) — Chief Executive Officer
- 2 Burlington Woods Drive, Suite 100, Burlington, MA 01803 (address) — Principal executive offices
- 333-276771 (registration_number) — Registration Statement Number
FAQ
When did Bone Biologics Corp file this S-1/A?
Bone Biologics Corp filed this Amended IPO Registration (S-1/A) with the SEC on February 26, 2024.
What is a S-1/A filing?
A S-1/A is a amendment to an IPO registration statement, typically incorporating SEC feedback. This particular S-1/A was filed by Bone Biologics Corp (BBLGW).
Where can I read the original S-1/A filing from Bone Biologics Corp?
You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by Bone Biologics Corp.
What are the key takeaways from Bone Biologics Corp's S-1/A?
Bone Biologics Corp filed this S-1/A on February 26, 2024. Key takeaways: Bone Biologics Corporation filed an S-1/A on February 26, 2024.. The filing is Amendment No. 2 to the Form S-1 Registration Statement.. The company is incorporated in Delaware and its fiscal year ends on December 31..
Is Bone Biologics Corp a risky investment based on this filing?
Based on this S-1/A, Bone Biologics Corp presents a relatively low-risk profile. The filing is an S-1/A, which is a routine amendment for a registration statement and does not contain new financial data or significant business updates that would alter the risk profile.
What should investors do after reading Bone Biologics Corp's S-1/A?
Monitor future filings for updates on the registration statement's effectiveness and details of the proposed public offering. The overall sentiment from this filing is neutral.
How does Bone Biologics Corp compare to its industry peers?
Bone Biologics Corporation operates in the orthopedic, prosthetic & surgical appliances & supplies industry.
Are there regulatory concerns for Bone Biologics Corp?
The filing is made under the Securities Act of 1933, which governs the registration of securities.
Industry Context
Bone Biologics Corporation operates in the orthopedic, prosthetic & surgical appliances & supplies industry.
Regulatory Implications
The filing is made under the Securities Act of 1933, which governs the registration of securities.
What Investors Should Do
- Review the full S-1/A filing for details on the securities being registered.
- Track the SEC's review process for the registration statement.
- Monitor for any subsequent amendments or the effectiveness of the registration statement.
Year-Over-Year Comparison
This is an amendment to a previously filed registration statement, not a new filing with updated financial performance data.
Filing Stats: 4,211 words · 17 min read · ~14 pages · Grade level 13.9 · Accepted 2024-02-26 16:50:51
Key Financial Figures
- $729,000 — titutional investors, for approximately $729,000. The warrants were sold in reliance on
Filing Documents
- forms-1a.htm (S-1/A) — 297KB
- ex10-18.htm (EX-10.18) — 78KB
- ex10-19.htm (EX-10.19) — 13KB
- ex10-18_001.jpg (GRAPHIC) — 6KB
- ex10-19_001.jpg (GRAPHIC) — 7KB
- 0001493152-24-007837.txt ( ) — 408KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Act of 1933, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized in the Town of Burlington, Commonwealth of Massachusetts, on February 26, 2024. BONE BIOLOGICS CORPORATION By: /s/ Jeffrey Frelick Name: Jeffrey Frelick Title: Chief Executive Officer (Principal Executive Officer) Signature Title Date /s/ Jeffrey Frelick Chief Executive Officer (Principal Executive Officer) February 26, 2024 Jeffrey Frelick * Chief Financial Officer (Principal Financial Officer and February 26, 2024 Deina H. Walsh Principal Accounting Officer) * Director February 26, 2024 Don R. Hankey * Director February 26, 2024 Siddhesh Angle * Director February 26, 2024 Robert Gagnon * Director February 26, 2024 Bruce Stroever * By: /s/ Jeffrey Frelick Attorney-in-Fact February 26, 2024 Jeffrey Frelick II-6